| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 68462-0135-08 | 68462-0135 | Abiraterone acetate | Abiraterone acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Oct 16, 2019 | In Use | |
| 40051-0609-53 | 40051-0609 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Aug 1, 2016 | In Use | |
| 00085-1417-03 | 00085-1417 | Temozolomide | Temodar | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 2, 2012 | In Use | |
| 62559-0925-51 | 62559-0925 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Nov 16, 2020 | Oct 31, 2022 | No Longer Used |
| 72205-0284-05 | 72205-0284 | Abiraterone acetate | Abiraterone | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | May 24, 2024 | In Use | |
| 69339-0168-03 | 69339-0168 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 5, 2023 | In Use | |
| 62175-0245-19 | 62175-0245 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Feb 10, 2016 | In Use | |
| 69238-1165-07 | 69238-1165 | Abiraterone | Abiraterone Acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Jan 7, 2019 | In Use | |
| 00480-4053-56 | 00480-4053 | Gefitinib | Gefitinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Oral | Jun 21, 2023 | In Use | |
| 57894-0184-12 | 57894-0184 | Abiraterone Acetate | Zytiga | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Apr 17, 2017 | Apr 18, 2017 | No Longer Used |
| 51862-0088-51 | 51862-0088 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Oct 10, 2016 | Sep 30, 2019 | No Longer Used |
| 75834-0146-05 | 75834-0146 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Dec 7, 2021 | In Use | |
| 00527-1782-55 | 00527-1782 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Mar 23, 2016 | May 24, 2018 | In Use |
| 00143-9597-21 | 00143-9597 | Abiraterone acetate | Abiraterone | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Nov 23, 2018 | In Use | |
| 59923-0713-05 | 59923-0713 | temozolomide | TEMOZOLOMIDE | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jan 25, 2019 | In Use | |
| 00173-0752-00 | 00173-0752 | Lapatinib | TYKERB | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Mar 16, 2007 | Nov 30, 2017 | No Longer Used |
| 57894-0150-25 | 57894-0150 | Abiraterone Acetate | Zytiga | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Sep 1, 2015 | Aug 31, 2018 | In Use |
| 23155-0779-71 | 23155-0779 | Temozolomide | Temozolomide | 250.0 mg/1 | Chemotherapy | Alkylating Agent | Tetrazine | Oral | Jun 15, 2022 | Jun 15, 2022 | No Longer Used |
| 72603-0110-01 | 72603-0110 | Abiraterone acetate | Abiraterone acetate | 250.0 mg/1 | Hormonal Therapy | Androgen Receptor Inhibitor | CYP17 Inhibitor | Oral | Mar 7, 2022 | In Use | |
| 68180-0801-36 | 68180-0801 | lapatinib | Lapatinib | 250.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR/HER2 | Oral | Sep 29, 2020 | In Use | |
| 55513-0002-01 | 55513-0002 | Darbepoetin alfa | Aranesp | 25.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
| 55513-0002-04 | 55513-0002 | Darbepoetin alfa | Aranesp | 25.0 ug/mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Sep 11, 2006 | In Use | ||
| 55513-0057-04 | 55513-0057 | Darbepoetin alfa | Aranesp | 25.0 ug/.42mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Aug 26, 2006 | In Use | ||
| 55513-0057-01 | 55513-0057 | Darbepoetin alfa | Aranesp | 25.0 ug/.42mL | Ancillary Therapy | Erythropoiesis-Stimulating Agent | Intravenous, Subcutaneous | Feb 18, 2011 | In Use | ||
| 82950-0012-01 | 82950-0012 | Tovorafenib | OJEMDA | 25.0 mg/ml | Chemotherapy | Enzyme Inhibitor | BRAF, CRAF | ORAL | Apr 30, 2024 | In Use |
Found 12611 results — Export these results
Home